Forte Biosciences Elects New Directors at Annual Meeting

Forte Biosciences ( (FBRX) ) has provided an update.

On May 29, 2025, Forte Biosciences held its annual meeting of stockholders, where 5,288,388 out of 6,583,382 shares were represented. During the meeting, Richard Vincent, Shiv Kapoor, and David Gryska were elected as Class II directors to serve until the 2028 annual meeting. Additionally, KPMG LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.

Spark’s Take on FBRX Stock

According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.

Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.

To see Spark’s full report on FBRX stock, click here.

More about Forte Biosciences

Average Trading Volume: 48,316

Technical Sentiment Signal: Sell

Current Market Cap: $55.17M

For detailed information about FBRX stock, go to TipRanks’ Stock Analysis page.